Open AccessCabergoline-induced Mania in a Patient of Pituitary Microadenoma
Author(s) -
Satyakam Mohapatra,
Mihir Ranjan Nayak
Publication year - 2017
Publication title -
indian journal of psychological medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 24
eISSN - 0975-1564
pISSN - 0253-7176
DOI - 10.4103/0253-7176.207314
Subject(s) - cabergoline , dopamine agonist , mania , agonist , prolactin , medicine , dopamine , dopamine receptor d2 , dopamine receptor , psychology , endocrinology , receptor , bipolar disorder , hormone , lithium (medication)
Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation. It is generally well tolerated as compared to other dopamine agonist agents due to its more selective D2 receptor agonistic effect. We present a case of a 25-year-old female who developed manic episode, following the use of cabergoline for treatment of pituitary microadenoma. We suggest that physicians should carefully screen patients before initiating cabergoline therapy and at-risk patients may benefit from more frequent monitoring and cessation of therapy at the earliest safe juncture.